Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
6.61
-0.38 (-5.44%)
Mar 31, 2025, 1:23 PM EDT - Market open
Immunome Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immunome stock have an average target of 26.6, with a low estimate of 21 and a high estimate of 33. The average target predicts an increase of 302.42% from the current stock price of 6.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +399.24% | Mar 20, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $30 | Buy | Reiterates | $30 | +353.86% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $35 → $25 | Strong Buy | Maintains | $35 → $25 | +278.21% | Mar 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +217.70% | Nov 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $30 | Buy | Initiates | $30 | +353.86% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
3.16M
from 9.04M
Decreased by -65.05%
Revenue Next Year
18.23M
from 3.16M
Increased by 476.80%
EPS This Year
-2.60
from -5.00
EPS Next Year
-3.03
from -2.60
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.5M | 50.4M | 161.2M | ||
| Avg | 3.2M | 18.2M | 78.6M | ||
| Low | n/a | n/a | 46.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5% | 1,494.9% | 784.3% | ||
| Avg | -65.0% | 476.8% | 331.3% | ||
| Low | - | - | 152.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | -1.89 | -1.42 | ||
| Avg | -2.60 | -3.03 | -2.62 | ||
| Low | -3.87 | -4.16 | -3.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.